Largest pharmaceutical companies in the United States by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
AbbVie leads the 44 pharmaceutical companies in the United States ranked by total liabilities, at CZK 3.06T, ahead of Pfizer (CZK 2.71T) and Johnson & Johnson (CZK 2.62T). Figures as of 20 Nov 2026, 10:50 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- AbbVieCZK 3.06T
- Median
- CZK 18.6B
- Combined market value
- CZK 83.31T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | CZK 3.06T | CZK 11.18T | CZK 6,323.00 | 0.86% down | 25% up | ||
| 2 | PfizerPFE · Health Care | CZK 2.71T | CZK 3.5T | CZK 614.15 | 1.85% down | 15% up | ||
| 3 | Johnson & JohnsonJNJ · Health Care | CZK 2.62T | CZK 14.34T | CZK 5,957.28 | 2.04% down | 34% up | ||
| 4 | Eli LillyLLY · Health Care | CZK 1.92T | CZK 26.84T | CZK 30,130.25 | 2.29% down | 33% up | ||
| 5 | Merck & CoMRK · Health Care | CZK 1.88T | CZK 7.3T | CZK 2,961.69 | 3.61% down | 45% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | CZK 1.6T | CZK 2.66T | CZK 1,300.99 | 2.05% down | 30% up | ||
| 7 | Abbott LaboratoriesABT · Health Care | CZK 756.9B | CZK 4.01T | CZK 2,316.32 | 0.58% down | 16% down | ||
| 8 | ViatrisVTRS · Health Care | CZK 501.3B | CZK 508.3B | CZK 443.33 | 1.97% down | 99% up | ||
| 9 | ZoetisZTS · Health Care | CZK 270.6B | CZK 732B | CZK 1,801.63 | 5.59% down | 26% down | ||
| 10 | Royalty PharmaRPRX · Health Care | CZK 220.9B | CZK 868.3B | CZK 1,510.17 | 1.38% down | 79% up | ||
| 11 | Regeneron PharmaceuticalsREGN · Health Care | CZK 207.4B | CZK 2.13T | CZK 20,590.67 | 2.35% down | 28% up | ||
| 12 | Vertex PharmaceuticalsVRTX · Health Care | CZK 155.6B | CZK 2.94T | CZK 11,610.82 | 2.94% down | 27% up | ||
| 13 | Elanco Animal HealthELAN · Health Care | CZK 151.9B | CZK 293B | CZK 586.27 | 1.54% down | 26% up | ||
| 14 | Alnylam PharmaceuticalsALNY · Health Care | CZK 93.2B | CZK 441.5B | CZK 3,296.42 | 1.06% down | 66% down | ||
| 15 | Amneal PharmaceuticalsAMRX · Health Care | CZK 81.9B | CZK 166.2B | CZK 477.00 | 2.24% down | 90% up | ||
| 16 | PTC TherapeuticsPTCT · Health Care | CZK 69.2B | CZK 108.7B | CZK 1,300.66 | 3.16% down | 21% down | ||
| 17 | Ionis PharmaceuticalsIONS · Health Care | CZK 67.7B | CZK 101.1B | CZK 607.01 | 0.62% down | 63% down | ||
| 18 | BridgeBio PharmaBBIO · Health Care | CZK 67.2B | CZK 339.6B | CZK 1,743.43 | 0.22% up | 21% up | ||
| 19 | CytokineticsCYTK · Health Care | CZK 46.5B | CZK 159.9B | CZK 1,147.57 | 0.27% up | 19% down | ||
| 20 | InsmedINSM · Health Care | CZK 34B | CZK 706.7B | CZK 3,221.49 | 20.58% up | 40% down | ||
| 21 | BioMarin PharmaceuticalBMRN · Health Care | CZK 33.6B | CZK 265.3B | CZK 1,369.68 | 0.02% down | 17% up | ||
| 22 | Arrowhead PharmaceuticalsARWR · Health Care | CZK 19.7B | CZK 137.6B | CZK 973.40 | 1.25% up | 13% up | ||
| 23 | United TherapeuticsUTHR · Health Care | CZK 17.5B | CZK 531B | CZK 12,468.04 | 3.16% down | 22% up | ||
| 24 | Legend BiotechLEGN · Health Care | CZK 16.3B | CZK 69.6B | CZK 359.03 | 0.92% down | 41% down | ||
| 25 | Madrigal PharmaceuticalsMDGL · Health Care | CZK 14.6B | CZK 205.5B | CZK 8,847.38 | 0.34% down | 27% down | ||
| 26 | Axsome TherapeuticsAXSM · Health Care | CZK 13.4B | CZK 159.2B | CZK 3,025.69 | 1.25% up | 6% down | ||
| 27 | Ligand PharmaceuticalsLGND · Health Care | CZK 12.1B | CZK 128B | CZK 6,398.82 | 3.94% down | 50% up | ||
| 28 | Mirum PharmaceuticalsMIRM · Health Care | CZK 11.8B | CZK 139B | CZK 2,129.89 | 3.27% up | 34% up | ||
| 29 | Travere TherapeuticsTVTX · Health Care | CZK 10.9B | CZK 103.4B | CZK 1,077.10 | 3.86% down | 45% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | CZK 9.3B | CZK 218.7B | CZK 1,446.84 | 1.88% down | 117% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | CZK 6.7B | CZK 107.6B | CZK 618.61 | 0.25% down | 20% down | ||
| 32 | Rhythm PharmaceuticalsRYTM · Health Care | CZK 4.7B | CZK 180.6B | CZK 2,604.66 | 1.88% down | 18% up | ||
| 33 | Corcept TherapeuticsCORT · Health Care | CZK 4.2B | CZK 158.6B | CZK 1,449.07 | 4.15% down | 10% down | ||
| 34 | Definium TherapeuticsDFTX · Health Care | CZK 2.4B | CZK 90B | CZK 657.41 | 1.24% up | 168% up | ||
| 35 | Summit TherapeuticsSMMT · Health Care | CZK 2.1B | CZK 188.5B | CZK 235.71 | 0.67% up | 36% down | ||
| 36 | ErascaERAS · Health Care | CZK 1.6B | CZK 111.3B | CZK 317.11 | 3.34% up | 395% up | ||
| 37 | Spyre TherapeuticsSYRE · Health Care | CZK 1.4B | CZK 206.8B | CZK 2,177.17 | 3.77% down | 332% up | ||
| 38 | Praxis Precision MedicinesPRAX · Health Care | CZK 1.3B | CZK 193.8B | CZK 6,933.13 | 1.87% up | 86% up | ||
| 39 | Protagonist TherapeuticsPTGX · Health Care | CZK 1.2B | CZK 180.5B | CZK 2,765.67 | 2.47% down | 51% up | ||
| 40 | Dianthus TherapeuticsDNTH · Health Care | CZK 836.7M | CZK 106.5B | CZK 1,891.73 | 1.01% up | 108% up | ||
| 41 | Edgewise TherapeuticsEWTX · Health Care | CZK 676.7M | CZK 100.5B | CZK 918.10 | 0.48% down | 86% up | ||
| 42 | Oruka TherapeuticsORKA · Health Care | CZK 372.1M | CZK 147.6B | CZK 2,175.83 | 1.91% up | 255% up | ||
| 43 | Belite BioBLTE · Health Care | CZK 224.6M | CZK 136.8B | CZK 3,367.78 | 3.33% down | 43% up | ||
| 44 | VeradermicsMANE · Health Care | CZK 204.2M | CZK 117B | CZK 2,773.92 | 0.38% down | 231% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 22.3002 CZK).
Questions and answers
Which pharmaceutical companies in the United States rank first by total liabilities?
AbbVie (CZK 3.06T), Pfizer (CZK 2.71T) and Johnson & Johnson (CZK 2.62T) are the top three of the 44 pharmaceutical companies in the United States ranked by total liabilities as of 20 Nov 2026, 10:50 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by total liabilities.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by total liabilities have a combined market value of CZK 83.31T as of 20 Nov 2026, 10:50 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by total liabilities”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.